Strategies to Enhance CAR-T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization.
Chimeric antigen receptor T (CAR-T) cell therapy has demonstrated remarkable clinical efficacy in treating hematological malignancies.
APA
Yu M, Yang T, et al. (2026). Strategies to Enhance CAR-T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization.. American journal of hematology, 101(2), 318-336. https://doi.org/10.1002/ajh.70131
MLA
Yu M, et al.. "Strategies to Enhance CAR-T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization.." American journal of hematology, vol. 101, no. 2, 2026, pp. 318-336.
PMID
41204883
Abstract
Chimeric antigen receptor T (CAR-T) cell therapy has demonstrated remarkable clinical efficacy in treating hematological malignancies. Nevertheless, the limited persistence of CAR-T cells in vivo remains a major therapeutic hurdle, leading to disease relapse. This review examines current strategies to enhance CAR-T cell durability, focusing on recent advances in CAR structural design, gene editing techniques, ex vivo culture optimization, clinical management approaches, and in vivo preparation. By integrating insights from preclinical studies and clinical trials, we provide a comprehensive analysis of methods to prolong CAR-T cell persistence from a technical perspective and discuss future directions.
MeSH Terms
Humans; Hematologic Neoplasms; Immunotherapy, Adoptive; Receptors, Chimeric Antigen; Gene Editing; Animals; T-Lymphocytes; Clinical Trials as Topic
같은 제1저자의 인용 많은 논문 (5)
- Nomogram Based on Tumor Burden Score and Inflammation-Nutritional Indicators to Predict the Prognosis of Hepatocellular Carcinoma Patients Undergoing TACE Combined with Targeted and Immunotherapy.
- The role of Alu elements in causing BRCA1 structural variation and breast cancer susceptibility.
- KRT16 and APOA1: key regulators of proliferation and lipid metabolism in non-small cell lung cancer.
- Metabolic reprogramming in cancer: dysregulation of glucose, lipid, and amino acid pathways and therapeutic opportunities.
- The dual roles of exosomes in prostate cancer: mechanisms in tumorigenesis and avenues for clinical translation.